AuthorisedPhase I and Phase II (Integrated)- First administration to humansInterventional

A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults

This research is looking into new vaccines designed to protect adults from two common lung infections: Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV). These viruses can cause colds, coughs, and sometimes more serious breathing problems, especially in older adults or those with underlying health conditions. The study is in its early stages (Phase I and II), meaning it’s the first time these vaccines are being tested in humans. The main goals are to find out if the vaccines are safe to use and to understand how effectively they help your body build up protection against these viruses. Volunteers will receive different doses of either a combined RSV/hMPV vaccine or an hMPV vaccine, and researchers will carefully monitor their health and immune response.

At a glance

Status

Authorised

Phase

Phase I and Phase II (Integrated)- First administration to humans

Sponsor

GlaxoSmithKline Biologicals

Enrolment target

464

Start

04 Jun 2026

Respiratory Syncytial Virus Infections+Metapneumovirus

What is this study about?

This study is about developing new vaccines to protect people from two common viruses that can cause breathing problems: Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV). You might not have heard of hMPV before, but it's a bit like RSV – both can cause cold-like symptoms, coughs, and sometimes more severe chest infections, particularly in older adults, young children, or those with weakened immune systems.

Vaccines work by teaching your body's immune system how to fight off a virus before you actually catch it. This study is testing new vaccines that could offer protection against one or both of these viruses. Because these are new vaccines, they are being tested in early stages (this is called Phase I and II). This means it's the first time they are being given to people.

The main aim is to carefully check if the vaccines are safe and to understand how well they help your body create a protective response against RSV and hMPV. By taking part, you would be helping scientists gather vital information that could lead to new ways to prevent these common and sometimes serious chest infections.

Key takeaways

This study is testing new vaccines for RSV and hMPV viruses in adults.
It's an early-stage study to check vaccine safety and how the body responds.
Participation involves receiving a vaccine and regular health checks.
The study aims to develop better protection against common chest infections.
Adults aged 18 and over can potentially take part.
You can withdraw from the study at any time.

Who may be eligible?

This study is looking for adult volunteers, aged 18 years and older. There is no upper age limit, so adults of all ages can potentially take part.

Both men and women are welcome to participate in this research project.

To find out if you can join, the research team will need to check your general health and medical history to make sure the study is a good fit for you. They will have specific rules about who can and cannot take part to ensure your safety and the quality of the study results.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you able to attend several study appointments?
Are you willing to receive a study vaccine injection?
Are you generally in good health (to be confirmed by study doctor)?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would be asked to attend several appointments at the study clinic or hospital. During these visits, the research team will explain everything to you in detail and answer any questions you have. You will then receive an injection of either a combined RSV/hMPV vaccine or an hMPV vaccine, depending on which group you are assigned to. Different doses will be tested.

Throughout the study, the team will monitor your health closely. This will likely involve regular check-ups, taking blood samples to see how your immune system is responding to the vaccine, and possibly asking you to keep a diary of any symptoms you experience. The total duration of your involvement in the study, including all visits and follow-ups, would be explained to you before you agree to participate.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. Potential benefits of joining this study include contributing to scientific knowledge about new vaccines for common respiratory viruses, which could help protect many people in the future. You will also receive careful medical monitoring. Potential risks might include common vaccine side effects like soreness, redness, or swelling at the injection site, or possibly mild fever, headache, or muscle aches. More serious side effects, though rare, are always a possibility with new medications or vaccines. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Belgium

Common questions

What are RSV and hMPV?

They are common viruses that can cause cold-like symptoms, coughs, and sometimes more serious chest infections.

What does a 'vaccine' do?

A vaccine helps your body learn to fight off a virus before you get sick, often preventing the infection or making it milder.

Is this vaccine already available to the public?

No, these are new vaccines being tested for the first time in people, so they are not yet available to the public.

Who can join the study?

The study is open to adults aged 18 and over, both men and women, after a health check by the research team.

What medicines will I receive?

You would receive an injection of either a combined vaccine for RSV and hMPV, or a vaccine just for hMPV.